• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers

    2/19/25 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email

    The acquisition will unlock a new level of personalized healthcare and deliver integrated offerings across nutrition, lifestyle, supplements, and medication

    Hims & Hers Health, Inc., the leading health and wellness platform, today announced its plans to introduce at-home lab testing through its platform. The new capability will empower customers to take control of their health with deeper insights and enable providers to access a breadth of data and biomarkers that can help identify risk of disease before it develops, for more precise clinical decision-making.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219392487/en/

    The acquisition will unlock a new level of personalized healthcare and deliver integrated offerings across nutrition, lifestyle, supplements, and medication. (Photo: Business Wire)

    The acquisition will unlock a new level of personalized healthcare and deliver integrated offerings across nutrition, lifestyle, supplements, and medication. (Photo: Business Wire)

    The company has acquired an at-home lab testing facility, Sigmund NJ LLC marketed as Trybe Labs, which will allow Hims & Hers to support at-home blood draws and more comprehensive whole body testing. The acquisition will broaden the company's ability to offer a wide range of personalized treatments, supplements and medications and accelerate the expansion into new high-impact clinical categories including low testosterone, perimenopausal and menopausal support.

    Using a blood lancet, which eliminates the need for needles or dried blood spot cards, customers will be able to learn more about their hormone levels, cardiac risk, stress markers, cholesterol, liver function, thyroid function, and prostate health. Providers on the platform will then be able to use that information as part of determining a personalized treatment plan most appropriate for their patient. In addition, de-identified lab data will accelerate the company's AI developments, including MedMatch by Hims & Hers, to get one step closer to delivering an AI-powered healthcare experience that can deliver access to affordable, high-quality care tailored to the individual.

    Customers come to the Hims & Hers platform to access treatment across chronic conditions. The company is already able to deliver access to quality and affordable care to more customers by leveraging its clinical expertise, seamless customer experience, and availability of treatment options customized for individuals. With affordable at-home lab testing, customers will be able to access more information about their health and providers can recommend high-quality customized treatments backed by more precise data for each individual patient.

    "The healthcare that customers expect and deserve today is on-demand care with treatments designed specifically for them. This next generation of healthcare is what we're building at Hims & Hers by providing the best information and set of options to each customer that comes to our platform so they can access precisely the care that is best for them," said Dr. Patrick Carroll, Chief Medical Officer of Hims & Hers. "Access to richer data allows us to deepen the insights that providers can use on our platform to guide their clinical decisions for each individual patient. At-home lab testing is one more exciting step towards elevating the personal, comprehensive care customers in this country should expect."

    Sigmund NJ LLC, marketed as Trybe Labs, is located in New Jersey. Hims & Hers funded the acquisition through cash on hand. The acquisition is complete, and Hims & Hers expects to roll out at-home testing to customers over the next year.

    For more information, visit www.hims.com/comprehensive-lab-testing.

    About Hims & Hers Health, Inc

    Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250219392487/en/

    Press Contact

    Abby Reisinger

    [email protected]

    Get the next $HIMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    1/12/2026$33.00In-line
    Evercore ISI
    12/9/2025$48.00Overweight
    Barclays
    10/21/2025Sector Weight
    KeyBanc Capital Markets
    6/23/2025Buy → Hold
    Needham
    6/4/2025$61.00 → $65.00Buy
    Needham
    4/29/2025$30.00Buy → Hold
    TD Cowen
    2/18/2025$42.00 → $60.00Overweight → Equal-Weight
    Morgan Stanley
    1/10/2025$24.00 → $25.00Neutral → Sell
    Citigroup
    More analyst ratings

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Hims & Hers Health with a new price target

    Evercore ISI initiated coverage of Hims & Hers Health with a rating of In-line and set a new price target of $33.00

    1/12/26 8:13:43 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Barclays initiated coverage on Hims & Hers Health with a new price target

    Barclays initiated coverage of Hims & Hers Health with a rating of Overweight and set a new price target of $48.00

    12/9/25 8:50:15 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    KeyBanc Capital Markets initiated coverage on Hims & Hers Health

    KeyBanc Capital Markets initiated coverage of Hims & Hers Health with a rating of Sector Weight

    10/21/25 7:20:02 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care

    The company will offer access to Galleri®, an innovative blood test from GRAIL, Inc. that screens for more than 50 types of cancer Today, Hims & Hers Health, Inc. (NYSE:HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a simple cancer screening blood test that can detect a signal for 50+ types of cancer even before symptoms appear1. This multi-cancer early detection (MCED) test combines Hims & Hers' scale with GRAIL's innovative cancer screening technology to dramatically increase access to proactive care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026

    2/4/26 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the c

    2/2/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Returns to the Big Game with a Message to All Americans: The Era of Health as a Luxury is Over

    New national spot "Rich People Live Longer" exposes America's economically-driven health gap, declaring that access to life-changing care belongs to everyone Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, announced that it's heading back to the Big Game this year. On February 8th, Hims & Hers will follow up its hit "Sick of the System" ad, debuting a new national spot "Rich People Live Longer" with a simple message: the era of health as a luxury good is over, and proactive, life-changing care belongs to everyone. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129852735/en/Ne

    1/29/26 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    SEC Filings

    View All

    SEC Form 144 filed by Hims & Hers Health Inc.

    144 - Hims & Hers Health, Inc. (0001773751) (Subject)

    12/22/25 5:00:50 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Other Events

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    11/17/25 8:04:04 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by Hims & Hers Health Inc.

    10-Q - Hims & Hers Health, Inc. (0001773751) (Filer)

    11/3/25 4:16:56 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    11/14/24 4:57:45 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/24 4:16:26 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Okupe Oluyemi exercised 9,067 shares at a strike of $6.27 and sold $275,114 worth of shares (9,067 units at $30.34) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    1/21/26 4:23:35 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Okupe Oluyemi exercised 5,986 shares at a strike of $9.16 and sold $306,453 worth of shares (9,070 units at $33.79), decreasing direct ownership by 3% to 91,617 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    1/7/26 4:16:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Okupe Oluyemi sold $824,710 worth of shares (23,090 units at $35.72), decreasing direct ownership by 20% to 94,333 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    12/23/25 4:15:46 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the future - where the power of technology will be combined with the best of personalized care. She will lead the company's global public policy, regulatory, and government affairs functions. A former senior leader at the FDA, prosecutor f

    11/17/25 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

    Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

    5/8/25 6:50:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer

    Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Nader Kabbani as Chief Operations Officer.1 A seasoned executive known for scaling trusted consumer and healthcare logistics businesses, Kabbani will oversee operations as the company expands access to personalized care for millions more individuals. This press release features multimedia. View the full release here: https://www.businesswire.com/ne

    5/5/25 9:01:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Financials

    Live finance-specific insights

    View All

    Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the c

    2/2/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results

    Revenue of nearly $600 million, up 49% year-over-year in Q3 2025 Net income of nearly $16 million; Adjusted EBITDA of over $78 million in Q3 2025 Subscribers grew to almost 2.5 million, up 21% year-over-year in Q3 2025 Narrows full year 2025 revenue guidance to $2.335 billion to $2.355 billion and Adjusted EBITDA guidance to $307 million to $317 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2025, in a shareholder letter that is posted at investors.hims.com. "This quarter we continued to prove that our vision of helping tens of mill

    11/3/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce Third Quarter 2025 Financial Results on November 3, 2025

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 3, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a missio

    10/13/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 12:09:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care